Keyora Multi-Mechanistic Nutritional Strategies for Pain Reduction, Structural Preservation, and Mobility Improvement in Osteoarthritis, Rheumatoid Arthritis Remission, Exercise-Induced Joint Stress, and NSAID-Intolerant Populations

This project is developed within the Keyora Joint Health Framework, a systems-based nutritional pharmacology model that emphasizes multi-mechanistic and clinically validated interventions for musculoskeletal disorders. The framework is built on the principle that joint health requires simultaneous support of pain modulation, cartilage preservation, synovial fluid optimization, and bone–immune regulation, rather than isolated single-target approaches. Within this Keyora framework, five core interventions are integrated: Undenatured Type II Collagen (UC-II), Glucosamine Sulfate, Plant-Based Chondroitin Sulfate, medium molecular weight Hyaluronic Acid (400 kDa), and Vitamin D₃. A distinctive feature of this framework is the use of plant-based chondroitin sulfate (300 mg/day), derived from renewable marine sources, which ensures higher purity, consistent molecular composition, and sustainability compared to conventional animal-derived CS. Together, these bioactives collectively address the continuum of joint disorders - from immune misrecognition to cartilage matrix depletion, lubrication loss, and inflammatory activation - providing a next-generation, safe, and sustainable model for joint health intervention. Core Interventions 1. UC-II (40 mg/day) induces oral tolerance via the GALT–Treg pathway, suppressing autoimmune-mediated synovitis. 2. Glucosamine sulfate (1500 mg/day) provides essential glycosaminoglycan substrates, supporting proteoglycan synthesis, inhibiting MMP-driven degradation, and improving extracellular matrix resilience. 3. Plant-based chondroitin sulfate (300 mg/day) delivers structurally consistent glycosaminoglycans from sustainable marine sources, enhancing proteoglycan matrix integrity, reducing cartilage catabolism, and supporting long-term joint resilience. 4. Hyaluronic acid (50 mg/day, 400 kDa) restores synovial viscosity, reduces frictional stress, and buffers inflammatory mediators. 5. Vitamin D₃ (10 µg/day) regulates Treg/Th17 balance and enhances osteo-articular stability. Differentiation of Plant-Based Chondroitin Sulfate Unlike traditional bovine- or porcine-derived CS, plant-based CS represents a new generation of glycosaminoglycan therapy. Its unique features include: - Higher purity and batch-to-batch consistency – free of animal-derived contaminants, ensuring safer and more reliable dosing. - Enhanced bioavailability – medium molecular weight fractions facilitate intestinal absorption and targeted cartilage uptake. - Sustainability and ethics – renewable plant origin aligns with global safety, environmental, and consumer preferences. These characteristics position plant-based CS as both clinically validated and future-oriented, offering superior translational value for long-term joint health interventions. Clinical Positioning Mechanistically, this integrative model spans five therapeutic axes: - Immune modulation (UC-II) - Structural reinforcement (Glucosamine sulfate) - Matrix preservation and sustainability (Plant-based CS) - Lubrication enhancement (Hyaluronic acid) - Inflammatory buffering and osteo-articular stability (Vitamin D₃) Supported by randomized controlled trials and international guidelines, this framework provides a safe, non-pharmacologic alternative or adjunct for: - Osteoarthritis - Remission-phase rheumatoid arthritis - Exercise-related joint strain - Spinal degeneration - NSAID-intolerant populations By integrating plant-based chondroitin sulfate as a dedicated pillar, the model advances both clinical efficacy and sustainability, representing a next-generation approach to joint health management.